Bechman et al. set out to describe the frequency and predictors of nonserious infections and compare incidence rates across biologic DMARDs. They found all bDMARDs are associated with a greater risk of nonserious infection, with differences observed between agents. Although unmeasured confounding must be considered, the magnitude of effect is large. [Read More]
Sponsored by Our Lab is Everywhere
Clinical evidence may help patients' changing needs.
See the story behind the moderate to severe RA study that reveals outcomes of one biologic monotherapy.USA-916-82440LEARN MORE